Generic Drug User Fee Rates for Fiscal Year 2027
The Federal Food, Drug, and Cosmetic Act (FD&C Act or statute), as amended by the Generic Drug User Fee Amendments of 2022 (GDUFA III), authorizes the Food and Drug Administration (FDA, Agency, or we) to assess and collect fees for abbreviated new drug applications (ANDAs); drug master files (DMFs); generic drug active pharmaceutical ingredient (API) facilities, finished dosage form (FDF) facilities, and contract manufacturing organization (CMO) facilities; and generic drug applicant program user fees. In this document, FDA is announcing fiscal year (FY) 2027 rates for GDUFA III fees.
Related coverage
- Statutorily Mandated Designation of Difficult Development Areas and Qualified Census Tracts for 2027
- Administrative Declaration of an Economic Injury Disaster for the State of Oregon
- Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information
- Reef Fish Fishery of the Gulf of America; Amendment 62
- Transparency in Coverage
- Adoption of Updated EDGAR Filer Manual